Initiator Pharma A/S, a clinical-stage pharma company developing innovative drugs targeting key unmet medical needs within the central and peripheral nervous system. Initiator Pharma is listed on First North Stockholm, Sweden (INIT). Initiator Pharma’s pipeline consists of three clinical programs – the clinical programs IP2018 and pudafensine for treatment of erectile dysfunction of psychogenic and organic origin, respectively, and a neuropathic pain program based on pudafensine. Furthermore, Initiator Pharma has recent announce that the drug candidates, pudafensine and IP2018, have shown significant efficacy in preclinical models for Female Sexual Dysfunction (FSD).
